Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
URGN Stock Forecast 2026-2027
$18.74
Current Price
$877.20M
Market Cap
Buy 7
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to URGN Price Targets
+193.5%
To High Target of $55.00
+81.4%
To Median Target of $34.00
-14.6%
To Low Target of $16.00
URGN Price Momentum
-20.2%
1 Week Change
-18.0%
1 Month Change
+80.4%
1 Year Change
-20.0%
Year-to-Date Change
-37.5%
From 52W High of $30.00
+448.0%
From 52W Low of $3.42
📊 TOP ANALYST CALLS
Did URGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if UroGen is one of their latest high-conviction picks.
Latest URGN Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, URGN has a bullish consensus with a median price target of $34.00 (ranging from $16.00 to $55.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $18.74, the median forecast implies a 81.4% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 193.5% upside. Conversely, the most conservative target is provided by Paul Choi at Goldman Sachs, suggesting a 14.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
URGN Analyst Ratings
7
Buy
1
Hold
0
Sell
URGN Price Target Range
Low
$16.00
Average
$34.00
High
$55.00
Current: $18.74
Latest URGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for URGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 5, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $33.00 |
| Oct 27, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Oct 27, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $40.00 |
| Oct 3, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Aug 19, 2025 | Piper Sandler | Kelsey Goodwin | Overweight | Initiates | $36.00 |
| Aug 11, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $40.00 |
| Aug 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Aug 5, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Jul 8, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $50.00 |
| Jul 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Jun 16, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Upgrade | $50.00 |
| Jun 13, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Jun 13, 2025 | Scotiabank | George Farmer | Sector Outperform | Maintains | $47.00 |
| Jun 13, 2025 | Guggenheim | Kelsey Goodwin | Buy | Maintains | $30.00 |
| Jun 12, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $25.00 |
| Jun 3, 2025 | Oppenheimer | Leland Gershell | Outperform | Maintains | $10.00 |
| May 23, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $15.00 |
| May 22, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Downgrade | $N/A |
| May 22, 2025 | Goldman Sachs | Paul Choi | Neutral | Maintains | $3.00 |
| May 13, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $55.00 |
Urogen Pharma Ltd. (URGN) Competitors
The following stocks are similar to UroGen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Urogen Pharma Ltd. (URGN) Financial Data
Urogen Pharma Ltd. has a market capitalization of $877.20M with a P/E ratio of -6.3x. The company generates $96.52M in trailing twelve-month revenue with a -170.6% profit margin.
Revenue growth is +9.0% quarter-over-quarter, while maintaining an operating margin of -99.7% and return on equity of +1,441.3%.
Valuation Metrics
Market Cap
$877.20M
Enterprise Value
$1.01B
P/E Ratio
-6.3x
PEG Ratio
-0.2x
Price/Sales
9.8x
Growth & Margins
Revenue Growth (YoY)
+9.0%
Gross Margin
+88.1%
Operating Margin
-99.7%
Net Margin
-170.6%
EPS Growth
+9.0%
Financial Health
Cash/Price Ratio
+14.5%
Current Ratio
4.0x
Debt/Equity
-1.1x
ROE
+1,441.3%
ROA
-34.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Urogen Pharma Ltd. (URGN) Business Model
About Urogen Pharma Ltd.
What They Do
Biopharmaceutical company focused on urological therapies.
Business Model
Urogen Pharma develops and commercializes innovative therapies targeting urological and uro-oncological diseases. It primarily generates revenue through the sale of its proprietary drug-delivery systems, which improve the efficacy of existing treatments while minimizing side effects.
Additional Information
The company is headquartered in Princeton, New Jersey, and Tamworth, UK, and aims to address unmet medical needs in the urologic oncology field. Its proprietary RTGel™ technology allows for targeted drug delivery, potentially transforming treatment options for conditions like low-grade upper tract urothelial carcinoma and non-muscle invasive bladder cancer.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
287
CEO
Ms. Elizabeth A. Barrett
Country
United States
IPO Year
2017
Website
www.urogen.comUrogen Pharma Ltd. (URGN) Latest News & Analysis
Latest News
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
10 days ago
Quick Summary
UroGen Pharma Ltd. announced news from Princeton, N.J., on January 5, 2026. Further details on the announcement were not provided in the excerpt.
Why It Matters
UroGen Pharma's announcement may signal developments in pharmaceutical innovations or financial performance, impacting stock prices and investment strategies in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Wildcat Capital Management sold 495,606 shares of UroGen Pharma in Q3, valued at approximately $6.79 million.
Why It Matters
Wildcat Capital's significant sale of UroGen Pharma shares may signal a lack of confidence in the company, potentially influencing market perception and stock price.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
UroGen Pharma granted inducement RSUs to 14 new employees to support the commercialization of its products Jelmyto® and ZUSDURI™, as well as ongoing pipeline development.
Why It Matters
UroGen's hiring indicates growth and commitment to its drug pipeline, potentially enhancing product commercialization and investor confidence in future revenue streams.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
UroGen Pharma Ltd. (Nasdaq: URGN) will present at the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, focusing on treatments for urothelial and specialty cancers.
Why It Matters
UroGen Pharma's presentation at a major healthcare conference may signal upcoming developments or partnerships, impacting stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
UroGen Pharma (URGN) is rated a Strong Buy, with a $33/share target by 2026. Its new drug, Zusduri, targets bladder cancer and is expected to drive profitability by 2027.
Why It Matters
UroGen Pharma's Strong Buy rating and $33 price target highlight strong growth potential from Zusduri in a large market, indicating significant upside and a path to profitability by 2027.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
UroGen Pharma Ltd. (URGN) will hold its Q3 2025 earnings call on November 6, 2025, at 10:00 AM EST, featuring key executives including the CEO and CFO.
Why It Matters
The earnings call provides insights into UroGen Pharma's financial health and strategic direction, influencing stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About URGN Stock
What is Urogen Pharma Ltd.'s (URGN) stock forecast for 2026?
Based on our analysis of 14 Wall Street analysts, Urogen Pharma Ltd. (URGN) has a median price target of $34.00. The highest price target is $55.00 and the lowest is $16.00.
Is URGN stock a good investment in 2026?
According to current analyst ratings, URGN has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.74. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for URGN stock?
Wall Street analysts predict URGN stock could reach $34.00 in the next 12 months. This represents a 81.4% increase from the current price of $18.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Urogen Pharma Ltd.'s business model?
Urogen Pharma develops and commercializes innovative therapies targeting urological and uro-oncological diseases. It primarily generates revenue through the sale of its proprietary drug-delivery systems, which improve the efficacy of existing treatments while minimizing side effects.
What is the highest forecasted price for URGN Urogen Pharma Ltd.?
The highest price target for URGN is $55.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 193.5% increase from the current price of $18.74.
What is the lowest forecasted price for URGN Urogen Pharma Ltd.?
The lowest price target for URGN is $16.00 from Paul Choi at Goldman Sachs, which represents a -14.6% decrease from the current price of $18.74.
What is the overall URGN consensus from analysts for Urogen Pharma Ltd.?
The overall analyst consensus for URGN is bullish. Out of 14 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $34.00.
How accurate are URGN stock price projections?
Stock price projections, including those for Urogen Pharma Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:44 AM UTC